Life Sciences partner Sophie McGrath and associate Kesten Laverty explain that women’s health and wellness industry has expanded exponentially over the last few years. Read the Maddyness UK article here.
Related Content
- Big Molecule WatchNovember 28, 2023
Regeneron Sues Samsung Bioepis for Proposed Biosimilar of EYLEA in West Virginia District Court
- Life Sciences PerspectivesNovember 27, 2023
A Practical Look at OIG’s New Compliance Guidance
- Big Molecule WatchNovember 22, 2023
Acuitas Files Suit Against CureVac Alleging Incorrect Inventorship on COVID MRNA-LNP Vaccine Patent Family
- AlertNovember 22, 2023
A Practical Look at OIG’s New Compliance Guidance
- Big Molecule WatchNovember 21, 2023
Genentech, Roche, and Biogen Sue Dr. Reddy’s and Fresenius for a Proposed Biosimilar of Rituxan in District of New Jersey
- Big Molecule WatchNovember 21, 2023
European Biologics Regulatory Updates
- Life Sciences PerspectivesNovember 17, 2023
Significant 340B Drug Pricing Program Litigation May Impact 340B Scope
- AlertNovember 17, 2023
Significant 340B Drug Pricing Program Litigation May Impact 340B Scope
- WebinarDecember 12, 2023
Contracting Away Your IP Rights: Pitfalls to Avoid With Third Party Partners During Drug Development
- Awards and RankingsNovember 30, 2023
The British Legal Awards Name Goodwin Editor’s Choice Law Firm of the Year
- WebinarNovember 29, 2023
Cell and Gene Therapies and Section 112: An Overview of the State of §112 Law and Considerations for Developers of Cell and Gene Therapies
- In the PressNovember 27, 2023
Goodwin Welcomes SEC Alum Lynn to Lead Public Companies Team (Bloomberg Law)
- In the PressNovember 27, 2023
Goodwin Strengthens Public Company Practice with New Hire (BNN)
- In the PressNovember 27, 2023
Goodwin Hires Ex-SEC Lawyer (Law360)
- In the PressNovember 27, 2023
Goodwin Hires Partner to Lead Public Company Practice (Reuters)
- Press ReleaseNovember 16, 2023
Q32 Bio and Homology Medicines To Merge